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ABSTRACT
TRAF1 is a member of the TRAF family, which plays
important roles in signal transduction that mediate
cell life and death in the immune response, inflam-
matory and malignant diseases. It is known that
TRAF1 transcription is inducible by various cyto-
kines, but little is known about the regulation of its
mRNA translation. In the present study, we
demonstrated that the human TRAF1 mRNA has an
unusually long 50-UTR that contains internal
ribosome entry segment (IRES) regulating its trans-
lation. By performing gene transfection and reporter
assays, we revealed that this IRES sequence is
located within the 572nt upstream from the AUG
start codon. An element between nt  392 and
 322 was essential for the IRES activity.
Interestingly, we found that the TRAF1 expression
is induced in cancer cells by chemotherapeutic
drug vincristine that regulates cytoplasmic localiza-
tion of polypyrimidine tract binding protein, which
may contribute to the IRES-dependent translation
of TRAF1 during vincristine treatment. These
results indicate that TRAF1 translation is initiated
via the IRES and regulated by vincristine, and
suggest that regulation of the IRES-dependent
translation of TRAF1 may be involved in effecting
the cancer cell response to vincristine treatment.
INTRODUCTION
TRAF1 is a member of the TRAF family that was origin-
ally identiﬁed based on its ability to interact with the cyto-
solic domain of tumor necrosis factor (TNF) receptor
type 2 (TNFR2) (1). To date, six members of the TRAF
family have been identiﬁed. All of these proteins share a
C-terminal TRAF domain, which is required for the
binding of these signal-transducing adaptors to TNFRs.
A more variable N-terminal domain, containing a ring
ﬁnger and several zinc ﬁnger motifs, is also found in all
TRAFs except TRAF1 (2). TRAF1 diﬀers from the other
TRAFs not only at the structural level, but also by its
tissue-speciﬁc expression (2,3). TRAF1 expression is re-
stricted to the normal cells of the spleen, lung and testis;
however, expression and even overexpression of this
protein occurs in many cancer cells, in particular the
lymphoid malignancies (4–8). TRAF1 expression can be
induced by stimulation with various cytokines, such as
TNF-a, IL-1 and CD40L (4,9). It has been reported that
cytokine-induced expression of TRAF1 occurs at the tran-
scriptional level (10,11). So far, no reports have studied
the regulation of TRAF1 expression at the translational
level.
It is postulated that the regulation of gene expression at
the level of translation plays an important role in
controlling gene expression that provides the cell with
the plasticity needed to respond to rapid changes in the
environment, such as cellular stress or apoptosis (12,13).
Initiation of translation can occur by two distinct mech-
anisms, cap-dependent scanning and internal ribosome
entry. The latter requires an internal ribosome entry
segment (IRES), located in the 50-UTR of the mRNA
(14). IRES elements are mainly found within the
mRNAs of proteins involved in regulating gene expression
during development, diﬀerentiation, cell growth and
apoptosis (15,16). The cap-independent (i.e.
IRES-dependent) translation represents a fail-safe mech-
anism for protein expression to progress when
cap-dependent translation is prevented or when the
leader sequence contains structural elements that inhibit
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becomes activated under conditions in which cap-
dependent protein synthesis is greatly reduced, such as
upon cellular stress and DNA damage, whereupon the
activated IRES initiates translation of only those speciﬁc
proteins that are able to protect cells from stress (19). It is
basically the energy-saving, cell-saving option for stressed
cells.
The IRES-dependent translation requires the presence
of an additional complex set of trans-acting factor/
ribonucleoprotein (RNP) participants for translational
activity to occur (14,20). Previous studies have shown
that several trans-acting factors and RNPs can regulate
IRES activity, including the polypyrimidine tract binding
(PTB) protein, which induces the translation of many
mRNA with IRES during cellular stress (21–24). The
trans-acting factor/RNP complexes bind to the IRES
region of mRNA, inducing the conformational changes
that facilitate recruitment of the ribosome to the IRES.
Because TRAF1 is an inducible protein that mediates
signals during cellular stress and apoptosis, we studied
TRAF1 to see whether its translation was regulated by
an IRES-dependent mechanism. In searching the TRAF1
gene from the Human Genome database, we found that
TRAF1 mRNA contains an unusually long 50-UTR. Thus,
we evaluated the potential for IRES elements within the
50-UTR of TRAF1 and looked for possible regulators of
IRES-mediated TRAF1 translation in cancer cells of
lymphoid origin, following treatment with several
chemotherapeutic drugs that are cell stress inducers.
MATERIALS AND METHODS
Cell lines and primary leukemia cells
Two lymphoid neoplastic cell lines, Raji and HDLM,
originating from human Burkitt lymphoma and
Hodgkin’s lymphoma, respectively, were used in this
study. Primary leukemia cells were derived at diagnosis,
from patients who were treated for acute lymphoblastic
leukemia (ALL) at Emory University’s clinical facilities.
Following informed consent, pre-treatment bone marrow
specimens containing primary leukemia cells were
obtained from eight patients with B-cell precursor (BCP)
ALL, as diagnosed by standard immunologic, morpho-
logic and cytochemical criteria. The mononuclear cells
were separated by centrifugation on Ficoll-Hypaque
(1.077gml
 1), washed twice in phosphate-buﬀered saline
(PBS) and resuspended at a density of 10
6 cells ml
 1 in
RPMI 1640 medium containing 10% fetal bovine serum
(FBS). The cells were incubated on plastic petri dishes for
one hour at 37 C to remove the monocytes, and then the
desired non-adherent cells were recovered by gently
washing the dishes. Following puriﬁcation, all specimens
collected contained more than 90% blasts.
Cell culture, reagents and treatment
Both the cell lines and primary leukemia cells were grown
in standard culture medium (RPMI 1640 containing 10%
FBS, 2mmoll
 1 of L-glutamine, 50 units penicillin and
50mgm l
 1 streptomycin) while incubated at 37 C in air
containing 5% CO2. All chemotherapeutic drugs tested,
including dexamethasone (DEXA), vincristine (VCR),
doxorubicin (Dox), methotrexate (MTX), cytarabine
(Ara-c) and L-asparaginase (L-Asp), were purchased
from Sigma. Cells were treated with a clinically relevant
range of concentration of each drug for the time period
indicated. Controlled experiments were performed using
one set of cells, and then repeated at least three times.
Plasmid construction
The full length as well as various deletions of the TRAF1
50-UTR cDNA were obtained by Reverse transcriptase
PCR (RT-PCR) from RNA extracted from the Raji cell
line. These TRAF1 50-UTR cDNAs were each inserted
immediately upstream from the translation start codon of
the ﬁrely luciferase (FL) gene in pGL3-Control (pGL3C)
plasmid at Hind III and Nco I sites, to generate the
monocistronic TRAF1 50-UTR-luciferase plasmids. The
dicistronic vector pRL-FL was kindly provided by Dr.
Steve Haines (University of Nottingham, UK). Also, the
full length and various deletions of TRAF1 50-UTR cDNA
were each inserted between RL and FL of the pRL-FL
vector at EcoR I and Nco I sites, to generate dicistronic
reporter plasmids. Many control plasmids were made sim-
ultaneously, including 50-UTR sequences with mutations
in the pGL3C and pRL-FL vectors and insertion of
an inverted repeat sequence, which forms a very stable
RNA hairpin structure, into the pRL-FL vector. All the
generated plasmids were DNA sequenced in order to
conﬁrm the presence and correctness of the TRAF1
50-UTR cDNAs in pGL3C and pRL-FL vectors. The
pSUPER/PTB siRNA plasmid was constructed by insert-
ing a speciﬁc 19nt PTB sequence 50-CAAAGGAGCCCA
GGGCTCT-30 into an expression plasmid, pSUPER-neo,
purchased from OligoEngine (Seattle, WA).
Gene transfection and reporter assay
Transient transfections were performed to identify the
presence of IRES activity in the TRAF1 50-UTR. Cells
were transfected with either monocistronic or dicistronic
TRAF1 50-UTR reporter plasmids by electroporation at
320V, 950 mF, using a Gene Pulser II System (Bio-Rad,
Hercules, CA). As an internal control, the pRL-CMV
vector was co-transfected with monocistronic plasmids.
Transfected cells were resuspended in 10ml of RPMI con-
taining 10% FBS, and then incubated 24–36h. Cell
extracts were prepared with 1  lysis buﬀer, then 20ml
aliquots of the supernatant were mixed ﬁrst with 100ml
of Luciferase Assay Reagent II (Promega) to measure
the FL activity and next, the RL activity was determined
by adding Stop & Glo Reagent to the same sample.
These luciferase activities were analyzed via Microplate
Instrumentation (BioTek).
Protein extraction and western blot analyses
Whole cell protein samples were prepared by lysing cells
for 30min at 4 C in a lysis buﬀer composed of 150mM
NaCl, 50mM Tris (pH 8.0), 5mM EDTA, 1% (v/v)
Nonidet p-40, 1mM phenylmethylsulfonyl ﬂuoride,
20mgm l
 1 aprotinin and 25 mgm l
 1 leupeptin.
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and cytoplasmic fractions were isolated using the NE-PER
kit (Pierce), according to the instructions of the manufac-
turer. Equal amounts of protein extracts were resolved by
sodium dodecyl sulfate–polyacrylamide gel electrophor-
esis (SDS–PAGE) and transferred to a nitrocellulose
ﬁlter. After blocking with buﬀer containing 5% non-fat
milk in 20mM Tris–HCl (pH 7.5) with 500mM NaCl for
1h at room temperature, the ﬁlter was incubated with
speciﬁc antibodies for 1h at room temperature, followed
by HRP-labelled secondary antibody. The blots were de-
veloped using a chemiluminescent detection system (ECL,
Amersham Life Science, Buckinghamshire, England).
RNA isolation and RT–PCR
The total RNA was extracted with the RNeasy Mini Kit
(Qiagen, Hilden, Germany) and was digested with
DNAse. RT–PCR was performed with an Access
RT–PCR Kit (Promega Corporation) according to the
manufacturer’s protocols. Reactions without addition of
reverse transcriptase (RT-) served as controls in experi-
ments to amplify the TRAF1 50-UTR. To speciﬁcally
amplify the 50-UTR of TRAF1 mRNAs, diﬀerent
primers were designed according to the corresponding se-
quences from the TRAF1 50-UTR mRNA. After electro-
phoresis on a 1.5% agarose gel, the PCR products were
visualized with ethidium bromide staining under UV light.
For testing TRAF1 mRNA expression, First-strand
cDNA synthesis was performed with a mixture of
random monamers and oligo-dT as primers (Qiagen).
Ampliﬁcation of TRAF1 was performed with a 7500
Real-Time PCR System (Applied Biosystems, Foster
City, CA), using a QuantiFast SYBR Green RT–PCR
kit (Qiagen), according to the manufacturer’s instructions.
The TRAF1 primers and the housekeeper gene GAPDH
were purchased from Qiagen (primer sequences not
provided). For testing the expression of FL and RL in
cells transfected with reporter plasmids, the primers used
were: For FL, forward 50-GGTGGACATCACTTACG
C-30 and reverse 5-GAAGGCTCCTCAGAAACA-3;
for RL, forward 50-AAAGGTGAAGTTCGTCGTCCA
AC-30 and reverse 50- TTTGAGAACTCGCTCAACGA
ACG-30.
Polysome preparation and analysis
Polysomes proﬁling was carried out essentially as
described previously (25) with slight modiﬁcations.
Brieﬂy, Raji cells, with or without exposure to VCR,
were incubated with 100mgml
 1 cycloheximide for
15min to arrest polyribosome migration. Cells were then
lysed to isolate cytoplasmic extracts in a buﬀer containing
20mM Tris–HCl at pH 8.0, 100mM NaCl, 5mM MgCl2,
0.5% Triton X-100, 500 U ml
 1 RNAsin and a cocktail of
protease inhibitors, followed by fractionation on 15–45%
(w/v) sucrose gradient. The gradient was centrifuged in
a SW41Ti rotor at 39000rpm for 1h. Fractions were
collected from each gradient tube by upward replacement
with monitored absorption at OD254 by using a
fractionator (Isco, Lincoln, NE). The RNA in each
fraction was extracted and subjected to real-time PCR as
described above.
Expression of GST-tagged PTB protein
The expression and puriﬁcation of GST-fused PTB
protein were performed as described previously (25).
Brieﬂy, after transfection of the GST-fused PTB plasmid
into BL21 Escherichia coli, the bacteria were incubated in
LB medium, and then harvested after incubation with
0.1mM IPTG for 2h. The puriﬁcation of GST-fused
PTB protein involved lysing of induced cells with sonic-
ation, followed by isolation of the complex with
glutathione-agarose beads (Pharmacia). The purity and
correct expression of the GST-fused PTB protein were
analyzed by gel electrophoresis with Coomassie G250
staining, plus a western blot assay using antibodies
against GST or PTB.
UV cross-linking and RNA binding assays
UV cross-linking and RNA binding assays were
performed as described previously (25). Brieﬂy, the
DNA templates for TRAF1 IRES from  392 to  322
(71 bases) with a T7 promoter for synthesis of the
TRAF1 IRES RNA probe (probe 1) was chemically
synthesized. The same 71 bases DNA fragment with mu-
tations at the CU-rich sequences ( 379 to  370 and  332
to 324) served as control (probe 2). Internally labelled
RNA probes were synthesized by in vitro transcription
with T7 polymerase (MAXIScript T7 RNA polymerase
kit, Ambion) in the presence of [a-
32P] UTP
(Amersham). Either GST-fused PTB or GST only
proteins were mixed with each of the
32P-labelled RNA
probes. UV cross-linking of the RNA–protein complexes
was performed using a 254-nm UV light source set at
400000mJc m
 2. The UV-irradiated RNA–protein
complexes were then treated with RNase T1, resolved by
10% SDS–PAGE gel and visualized by autoradiography.
For in vivo association between PTB protein and
TRAF1 IRES, TRAF1 mRNA was
co-immunoprecipitated from whole-cell extracts by using
the modiﬁed as described previously (25). Brieﬂy, cultured
Raji cells were harvested by low-speed centrifugation at
4 C. The cell pellets were resuspended in 100ml of RNA
binding buﬀer [20mM Tris (pH 7.5), 150mM NaCl, 5mM
MgCl2, 0.1% NP-40, 50mM ZnCl2, 2% glycerol, 1mM
DTT] that was supplemented with 10U of RNase inhibitor
(50–30), then cell extracts were prepared by the freeze-thaw
method. To whole-cell extracts, 5ml of monoclonal
anti-PTB antibody or the anti-actin antibody, 20mlo f
protein A plus G agarose beads, and 5 U of RNase in-
hibitor were added, after which the samples were
incubated for 60min at room temperature. Next, the
beads were washed extensively with RNA-binding buﬀer
supplemented with RNase inhibitor. The RNA associated
with the antibody–antigen complexes was isolated by
repeat phenol–chloroform extractions and precipitation
with 2M ammonium acetate and 3 volumes of cold
ethanol. The RNA was then analyzed by RT–PCR,
using TRAF1 IRES-speciﬁc primers.
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Identiﬁcation of the long 50-UTR within TRAF1 mRNA
We searched the Human Genome database (http://www.
ensembl.org/index.html) and found that only TRAF1, but
not other TRAF members, has an unusually long 50-UTR.
The 50-UTR lengths for the TRAF family are 2446 bases
for TRAF1 (Figure 1A and B), 55 bases for TRAF2, 353
bases for TRAF3, 108 bases for TRAF4, 54 bases for
TRAF5 and 340 bases for TRAF6. We performed
RT–PCR on cancer cell lines and primary leukemia
cells, demonstrating and conﬁrming the presence of the
50-UTR of TRAF1 mRNA in all cancer cells studied
(Figure 1C and D).
Analysis of IRES activity within the 50-UTR of TRAF1
mRNA
To investigate the possibility that the TRAF1 50-UTR
may have IRES activity, we divided the entire 2446
bases 50-UTR of TRAF1 into three parts ( 2446 to
 1587,  1586 to  573 and  572 to  1) and cloned
each of them into the pGL3C plasmid immediately
upstream of the FL translation start codon, to generate
monocistronic plasmids (Figure 2A). The SV40
promoter-driven FL activity in this plasmid could be
aﬀected by any insertion between the promoter and FL
gene. For example, if the insertions have IRES activity,
the FL activity in cells transfected with this plasmid would
not be inhibited, or may even be enhanced. As shown in
Figure 2(B), when the plasmids were transfected into Raji
cells, the insertions with the  2446 to  1587 and  1586 to
 573 sequences inhibited FL activities as compared to
pGL3C, suggesting that these sequences have no IRES
activity. In contrast, the  572 to  1 fragment increased
FL activity, suggesting that this fragment has IRES
activity. Insertion into pGL3C of the same  572 to  1
fragment in a reverse orientation blocked FL activity,
further conﬁrming that the forward  572 to  1
sequence of the TRAF1 50-UTR has IRES activity.
To further assess the IRES activity of the  572 to  1
fragment, we cloned it into the pRL-FL vector to generate
various dicistronic plasmids (Figure 2C). Transfection of
the pRL-FL vector alone into Raji cells showed RL
activity, but not FL activity (Figure 2D). However, FL
Figure 1. (A) Schematic illustration of the TRAF1 mRNA structure containing a long 50-UTR (from  2446 to  1). The translation start codon
AUG located 226 bases from the 50 border of exon 2. (B) DNA sequence of the TRAF1 50-UTR. The start codon ATG is highlighted and a potential
IRES sequence is underlined. (C) RT–PCR products indicate that TRAF1 50-UTR was expressed by all cancer cells studied, including the two
lymphoma cell lines (Raji and HDLM) and primary ALL cells from two patients (UPN 1 and UPN 2) shown. The primers used for PCR
ampliﬁcation were designed from the corresponding areas on TRAF1 50-UTR, to synthesize the three fragments indicated. (D) RT–PCR was
performed using the same primers as in (C) and total Raji RNA that was digested with or without DNAse, in the presence or absence of RT.
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with pRL-FL containing the  572 to  1 fragment, while
the RL activity level was similar to pRL-FL alone. To
ensure that it was an eﬀect of internal ribosome entry
rather than enhanced ribosomal read through or
re-initiation, an inverted repeat sequence, which forms a
very stable RNA hairpin structure, was inserted into the
upstream RL cistron (Figure 2C). As shown in
Figure 2(D), this inserted hairpin absolutely inhibited
the cap-dependent translation of RL, while the presence
of the  572 to  1 fragment of TRAF1 50-UTR in the
constructor allows initiation of FL translation. The FL
activity stimulated by the  572 to  1 fragment with the
hairpin added (phpRL-FL) was comparable to that of the
transfected with pRL-FL containing the fragment without
the hairpin. These results conﬁrmed that the FL activity
induced in the dicistronic plasmid was indeed stimulated
by that  572 to  1 fragment that can act as IRES does,
and was not a product of enhanced ribosomal read
through or re-initiation.
Furthermore, we performed RT–PCR analyses of
mRNA expression of FL in cells transfected with
Figure 2. Analysis of IRES activity in the 50-UTR of TRAF1. (A) Schematic representation of the monocistronic plasmids used for the reporter
assays. The entire 2446 bases TRAF1 50-UTR was divided into three sections ( 2446 to  1587,  1586 to  573 and  572 to  1) and each was
cloned into pGL3C plasmid immediately upstream from the translation start codon of the ﬁreﬂy luciferase (FL) gene. (B) Transfection and reporter
assay for IRES activity of TRAF1 50-UTR. Raji cells were each co-transfected with 5mg of pGL3C-TRAF1-50UTR plasmid and 1mg of pRL-SV40
vector as an internal control, by electroporation, and then quantitative RL and FL activities were detected using the Dual-Luciferase Reporter
System. Data represent the mean ± SD of three independent experiments normalized to RL activity. (C) Schematic representation of the dicistronic
constructs used for the reporter assays. The phpRL-FL is similar to pRL-FL, but with the addition of a stable hairpin at the 50-end of the RL
transcript to suppress cap-dependent translation of RL. (D) RL and FL activity analyses following transfection of Raji cells with 5mg of each
plasmid indicated, including pRL-FL and phpRL-FL vectors and constructions of these vectors with insertion of the fragment  572 to  1 of the
TRAF1 50-UTR. (E) RL and FL mRNA levels analyses following transfection of cells with various plasmids as described in (D). Total RNA was
extracted, and RT–PCR was performed with speciﬁc primers targeted to FL and RL.
Nucleic Acids Research, 2010,Vol.38, No. 13 4507dicistronic reporter plasmids. We found that FL mRNA
expression was not altered by insertion of the  572 to  1
fragment (Figure 2E), which suggested that the
fragment-stimulated FL activity occurs solely at the trans-
lational level.
Mapping the TRAF1 IRES
To further determine the core IRES region within the
TRAF1 50-UTR, we generated dicistronic plasmids con-
taining a series of deleted fragments of the  572 to  1
sequence (Figure 3A). Each of these plasmids was trans-
fected into Raji cells. Upon assessment of their luciferase
activities, we discovered that the core IRES region con-
tained 71 bases and resided between  392 and  322. As
shown in Figure 3B, the construct  392 to  1 expressed
maximal FL luciferase activity similar to that of the
full-length fragment  572 to  1, while  322 to  1
showed a signiﬁcant reduction (approximately a 7-fold
decrease) of FL activity. To further conﬁrm that the
sequence between  392 and  322 is critical for TRAF1
IRES activity, we cloned that 71 bases sequence into the
pRL-FL vector, where it stimulated FL activity compar-
able to that of the larger  572 to  1 fragment.
Previous reports have described the molecular cloning
of the promoter of the human TRAF1 gene, and the
putative TRAF1 promoter region proposed includes
intron 1 and part of the 50-UTR of TRAF1 mRNA
(9,26). To clarify whether the 71 bases sequence between
 392 and  322 of the TRAF1 50-UTR acts as a promoter
to stimulate FL activity when it is inserted into the
pRL-FL vector, we cloned this 71 bases fragment into
the pGL3-basic vector (Figure 3C). We also cloned the
intron 1 and the 50-ﬂank of the 50-UTR of TRAF1 into
the pGL3-basic vector, to serve as controls. By similar
transfections and reporter assays in Raji cells, we found
that the 71 bases sequence between  392 and  322 did
not stimulate FL activity in the pGL3-basic vector. In
contrast, the intron 1 DNA sequence of TRAF1 gene
stimulated FL activity (Figure 3D), but not the FL
activity in the pRL-FL vector when inserted between the
RL and FL cistrons (data not shown). Our results also did
not show any promoter activity of the 50-ﬂank of the
50-UTR mRNA. Taken together, these results clearly
demonstrated that only the 71 bases sequence between
 392 and  322 is IRES that can regulate TRAF1 trans-
lation, and it is not a promoter mediating TRAF1
transcription.
Figure 3. Deletion mapping for identiﬁcation of TRAF1 IRES. (A) Schematic representation of dicistronic pRL-FL constructs containing a series of
50–30 or 30–50 deleted TRAF1 50-UTR fragments. (B) Raji cells were transfected with 5mg of each indicated plasmid. After 24h, luciferase activities
were tested. Data represent the mean ± SD of luciferase activity of FL versus RL in at least three independent experiments. (C) Schematic
representation of pGL3-basic vector with diﬀerent inserts, including the  392 to  322 fragment of the TRAF1 50-UTR, the putative TRAF1
promoter regions of the 50-ﬂank of the TRAF1 50-UTR and the intron 1 of the TRAF1 gene. (D) Transfection and luciferase activity assays were
performed as described in Figure 2B. Transfection of pGL3-basic vector without insert served as control. Data represent the mean ± SD of three
independent experiments normalized to RL activity.
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expression by vincristine
It is known that for certain mRNAs, IRES-mediated ini-
tiation of protein translation is activated during condi-
tions such as cellular stress and apoptosis. To investigate
whether the IRES-mediated translation of TRAF1 is
aﬀected during cellular stress, we examined both TRAF1
IRES activity and TRAF1 protein expression in leukemia
cells treated with various stress inducers. Western blot
assays were performed to examine TRAF1 protein expres-
sion in primary ALL cells treated with the stress cytokine
TNF-a, as well as a series of chemotherapeutic drugs
(DEXA, VCR, Dox, MTX, Ara-c and L-Asp) that are
frequently used in the treatment of ALL. While primary
ALL cells derived from patient bone marrow generally
express no or very low levels of TRAF1 (Figure 4A and
B), TNF-a treatment induced expression of TRAF1 as
well as several other TRAFs. Surprisingly, we found
that TRAF1 expression in ALL cells was only induced
by VCR, but not other chemotherapeutic drugs
(Figure 4A). Furthermore, among the TRAF family
members tested, only TRAF1 was induced by VCR.
After studying cells from eight ALL patients, we con-
ﬁrmed that VCR induced expression of TRAF1 in all of
them, although the levels of TRAF1 diﬀered from case to
case (Figure 4B). In addition, we found the VCR-induced
TRAF1 expression was dose and time dependent
(Figure 4C).
To evaluate whether VCR, like TNF-a, induces TRAF1
mRNA expression, we performed RT–PCR to examine
TRAF1 mRNA expression in ALL cells that were
treated with VCR. Results, as shown in Figure 4D,
demonstrated that VCR did not induce TRAF1 transcrip-
tion whereas TNF-a induced TRAF mRNA expression
(data not shown). These results imply that VCR-induced
TRAF1 expression might occur at the translational level.
We performed gene transfections and reporter assays to
see if VCR induced TRAF1 IRES activity. The lymphoma
cell line Raji was transfected with the pRL-FL plasmid
containing the TRAF1 50-UTR sequence from  392 to
 1 (pRL-392-FL) and then treated the transfected cells
Figure 4. Induction of TRAF1 translation by vincristine in cancer cells. (A) Fresh isolated leukemic cells from an ALL patient was treated with 1 mg
ml
 1 DEXA, 0.5 mgm l
 1 Dox, 0.5mgm l
 1 VCR, 0.5 mgm l
 1 MTX, 0.5 mgm l
 1 Ara-c, 1IU/mlL-Asp and 0.05 mgm l
 1 TNF-a, respectively, for
24h. The protein expression for diﬀerent TRAFs was examined by western blot analysis. (B) Fresh leukemic cells from eight ALL patients (UPN,
unique patient number) were incubated with 0.5mgm l
 1 VCR for 24h (T). The expression of TRAF1 in each was detected by western blot assay as
compared with untreated cells (C). (C) Time- and dose-dependent induction of TRAF1 protein expression in ALL cells treated with VCR. Leukemia
cells from UPN 1 were treated with 0.5 mgm l
 1 VCR for diﬀerent times or with VCR for 24h at diﬀerent doses, as indicated. Protein expression was
examined by western blot. (D) mRNA expression levels of TRAF1 after treatment with or without increasing concentrations (0.01, 0.1 and 1mgml
 1)
of VCR in Raji cells, as determined by quantitative RT–PCR. (E) Transfection and reporter assay for the eﬀect of VCR on TRAF1 IRES activity.
Raji cells were transfected with 5mg pRL-392-FL plasmid containing TRAF1 IRES from  392 to  1 fragment and treated with or without
increasing concentration (0.01, 0.1 and 1mgml
 1) of VCR. Data represented the mean ± SD of RL and FL activities in at least three independent
experiments. (F) Raji cells were treated with or without 0.5 mgm l
 1 VCR for 24h, and cytoplasmic lysates were fractionated on sucrose gradient.
RNA was extracted from each of the fractions and subjected to quantitative RT–PCR for quantitative analysis of the distribution of TRAF1 and
Actin mRNAs. Data represent percentage of the total amount of corresponding mRNA on each fraction.
Nucleic Acids Research, 2010,Vol.38, No. 13 4509with VCR. We found that VCR increased the FL (TRAF1
IRES) activity (Figure 4E). Furthermore, we performed
linear sucrose gradient fractionation to assess the poly-
ribosome association of the TRAF1 mRNA in Raji cells
subjected to VCR and mock treatment. We found that
TRAF1 mRNA was clearly shifted from fractions con-
taining translation dormant complexes including
mRNPs, ribosome subunits, and monosomes (Figure 4F,
bottom, fractions 1–4) to fractions enriched of translating
polyribosomes (Figure 4F, bottom, fractions 5–11). This
observation was likely speciﬁc, because VCR treatment
had no eﬀect on the polyribosome proﬁle of Actin
mRNA (Figure 4F, top), thus demonstrating that induc-
tion of TRAF1 by VCR occurred at the translational
level.
Subcellular redistribution of PTB induced by vincristine
confers TRAF1 translation
A previous study shows that VCR induces translocation
of the PTB protein from the nucleus to the cytoplasm,
where it induces BAG-1 IRES in HeLa cells (24). We
wondered whether VCR induces TRAF1 IRES-mediated
translation through a similar mechanism as for BAG-1
induction. Our study was performed in Raji cells that
express high levels of both PTB and TRAF1 proteins.
VCR treatment of Raji cells produced similar results as
in HeLa cells, as expression of nuclear PTB was decreased
and cytoplasmic PTB was signiﬁcantly increased
(Figure 5A). As also shown in Figure 5A, VCR treatment
did not aﬀect total cellular PTB expression, suggesting
that the increased PTB in the cytoplasm was derived
from the translocation of nuclear PTB.
Because it is known that PTB physically interacts with
speciﬁc RNA structures within IRES elements in the cyto-
plasm to regulate IRES-dependent translation, we tested
the ability of PTB to bind to the TRAF1 IRES. We ﬁrst
performed IP and RT–PCR to search for possible associ-
ation in vivo between the PTB protein and the TRAF1
mRNA, and found that the PTB protein was able to
bind TRAF1 mRNA (Figure 5B). Then, a protein–
RNA-binding assay with UV cross-linking of the
32P-labelled TRAF1 IRES probes and the recombinant
GST-fused PTB protein, we were able to show that the
PTB protein speciﬁcally bound to the CU-rich sequences
of the TRAF1 IRES RNA (Figure 5C).
To further evaluate whether PTB regulates TRAF1
IRES-mediated translation, we performed gene transfec-
tions followed by reporter assay as well as western blot
assays to examine both TRAF1 IRES activity and the
endogenous TRAF1 protein expression under conditions
where PTB is silenced by siRNA. For this, we generated a
pSUPER/PTB plasmid containing a 19nt siRNA
sequence speciﬁc for targeting PTB. Transfection of this
plasmid into Raji cells signiﬁcantly suppressed endogen-
ous PTB expression (Figure 5D). As also seen in
Figure 5D, we observed a reduced expression of the
endogenous TRAF1 protein in those PTB
siRNA-transfected Raji cells. We also found that
co-transfection of the PTB siRNA plasmid with the
pRL-392-FL reporter plasmid into Raji cells remarkably
decreased the activity of FL (Figure 5E).
DISCUSSION
In this report, we describe the identiﬁcation and analysis
of the 50-UTR region of TRAF1 mRNA as well as its
possible role in the regulation of translation, with the
goal of gaining insight into the properties of TRAF1 in
regulating the life and death of cancer cells. By searching
the Human Genome database, we discovered that the
TRAF1 mRNA contains an unusually long 50-UTR.
When cloned into the luciferase reporter vectors and
transfected into lymphoid cancer cells, the 50-UTR of
the TRAF1 mRNA showed considerable IRES activity.
By performing deletion mapping, the core IRES region of
the TRAF1 mRNA was found to be located between
 392 and  322. It turned out that this IRES region con-
tained two copies of CU-rich sequences that promoted
interaction with and regulation by PTB protein. We also
found that unlike many other anticancer drugs, the
chemotherapeutic drug VCR, which is able to induce
subcellular redistribution of PTB, uniquely stimulated
TRAF1 translation in cancer cells of a lymphoid origin.
Unlike other TRAF proteins that are more ubiquitously
expressed throughout the human body, the in vivo expres-
sion of TRAF1 is the most restricted, suggesting that the
expression of TRAF1 is highly regulated. The expression
of genes is mainly regulated at the transcriptional level;
however, evidence is growing in support of the concept
that translational regulation also plays an important role
in the control of gene expression (27). In particular, the
translation of certain mRNAs via a speciﬁc
cap-independent mechanism is involved in a diverse
range of cellular activities, including proliferation,
growth and apoptosis (28). Our present study veriﬁed
that cap-independent (IRES-dependent) mechanism
plays a critical role in TRAF1 translation. For this
study, we only analyzed the TRAF1 IRES activity in
lymphoid cancer cells. Still to be investigated is the signiﬁ-
cance of IRES-mediated TRAF1 translation in both
non-lymphoid cancer cells and in normal cells. For
example, evidence must still be collected to demonstrate
whether the IRES-mediated translation is responsible for
the restricted expression of TRAF1 in various types of
normal cells, due to ineﬃcient or lowered levels of
cap-dependent translation, and whether IRES-mediated
TRAF1 translation could be cell-type speciﬁc, helping to
explain why there is TRAF1 expression in only certain
types of cells.
An important ﬁnding of our present study is that
IRES-regulated TRAF1 translation is activated during
the treatment of lymphoid cancer cells with the
chemotherapeutic drug VCR. Treatment with VCR sig-
niﬁcantly increased the expression of endogenous
TRAF1 protein, which was maintained at high levels for
up to 48h following VCR exposure in the BCP ALL cells.
Interestingly, VCR did not regulate TRAF1 mRNA ex-
pression, suggesting that the observed increase in protein
expression occurred at the translational level. Transfection
4510 Nucleic Acids Research, 2010,Vol.38, No. 13and reporter assay indeed demonstrated that VCR
stimulated the TRAF1 IRES activity that mediates a
speciﬁc cap-independent translation. Even more notable
was the fact that only VCR induced TRAF1 expression
in ALL cells, but not any other cell-stressing
chemotherapeutic drugs including DEXA, Dox, MTX,
Ara-c and L-Asp. These observations suggest that not
all stress and apoptosis inducers can regulate
IRES-dependent TRAF1 translation and that a rather
speciﬁc or unique cellular mechanism or signaling
cascade existed in ALL cells (and potentially other
cancer cells) that was able to regulate or promote
VCR-induced TRAF1 IRES activity. Translated to an
in vivo situation, it could mean that ALL, and perhaps
other cancer cells, have a greater ability to evade death
during VCR therapy, compared with other drugs.
It has been reported that VCR can induce cytoplasmic
translocation of PTB, which can in turn regulate BAG-1
IRES-mediated translation (24). Consistent with that ob-
servation, our results showed that VCR induces relocation
of PTB from the nucleus to the cytoplasm in Raji cells.
Although the mechanism by which PTB regulates
Figure 5. Vincristine-modulated PTB that binds to the TRAF1 IRES and regulates TRAF1 translation. (A) Raji cells were treated with 0.5mg/ml
VCR for diﬀerent times, then cell extracts were tested for both nuclear (Nuc) and cytoplasmic (Cyt) expression of PTB, as well as for total PTB in
the whole cell extracts (WCE), by western blot assays. (B) cell extracts from Raji were prepared in RNA-binding buﬀer in the presence of RNase
inhibitor (RNasin). Following co-IP with anti-PTB and anti-actin (control), the TRAF1 mRNA was detected by RT–PCR analysis. IP without
addition of RNasin and antibody (lane 1) and with anti-PTB but no RNasin (lane 2) were done as additional controls. The negative (no template,
lane 5) and positive (Raji RNA as template, lane 6) controls for RT–PCR are also shown. (C) the GST-fused PTB protein and GST only were
incubated, respectively, with
32P-labelled RNA probes corresponding to the wild-type (probe 1) and mutant (probe 2) TRAF1 IRES  392 to  322
elements. Protein/RNA complexes were UV cross-linked, run on an SDS–PAGE gel, and imaged by autoradiography. The reactions of GST-PTB
protein and probes with prior addition of RNA competitor (lanes 1 and 5) or without UV exposure (lanes 3 and 7) were included as additional
controls. (D) Raji cells were transfected with diﬀerent amounts of pSUPER plasmids containing either PTB siRNA or a control siRNA for 24h. The
expression of endogenous PTB and TRAF1 was detected by western blot assay. (E) Raji cells were co-transfected with 5mg pRL-392-FL and with
increasing amounts (1, 5 and 10 mg) of pSUPER PTB or pSUPER control. Controls also include transfection of a plasmid pRL-392 (m)-FL
containing the  392 to  1 fragment with mutations at the CU-rich sequences and a plasmid pRL-392 (r)-FL containing the  392 to  1
fragment in a reverse (r) orientation. Quantitative RL and FL were detected using the Dual-Luciferase Reporter System. Data represents the
mean ± SD luciferase activity of FL versus RL, in at least three independent experiments.
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understood, it is known that cytoplasmic PTB can
directly bind to a CU-rich sequence within the cellular
IRES and regulate its activity (23,29). By analysing the
active 71 bases TRAF1 IRES region, we found that it
contains two CU-rich sequences (CUUCUUUUUU and
CUUCUCCUU). We then demonstrated that PTB bound
to the 71 bases TRAF IRES. In addition, we showed that
the silencing of PTB expression in TRAF1-overexpressing
Raji cells resulted in the inhibition of TRAF1 IRES
activity and TRAF1 protein expression as well. These
results indicate that IRES-mediated TRAF1 translation
was regulated by PTB, which may be the most likely
mechanism by which VCR treatment induced TRAF1 ex-
pression, i.e. through its modulation of the PTB protein.
It is reported that TRAF1 is typically overexpressed in
B-cell lymphoid malignancies, including Hodgkin and
non-Hodgkin lymphomas and chronic lymphoblastic
leukemia (4–7). In the present study, we found that the
early BCP ALL express no or very low levels of TRAF1
endogenously, although TRAF1 can be induced in these
cells by VCR. This appears to imply that constitutive
TRAF1 overexpression is associated with the maturation
of B cells and the development of B-cell lymphoma.
Despite the current observation that it is deregulation of
the signaling pathways that regulate NF-kB that causes
the overexpression of TRAF1 transcripts in
lymphomagenesis (8), it is possible that aberrant regula-
tion of TRAF1 translation through other pathways may
also play a role in the development of lymphoma. At least
one may have been uncovered here: We, for the ﬁrst time,
have identiﬁed that the translation initiation of TRAF1 is
regulated by an IRES-dependent mechanism. Further
studies evaluating other trans-acting factors, in addition
to PTB, that could also regulate TRAF1 IRES activity
may allow us to better understand the magnitude of the
biological role of TRAF1 in lymphomagenesis and resist-
ance to therapy.
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